Mustbio is dedicated to developing innovative, multispecific immuno-oncology therapies

  • Research
Program Target Indication POC Candidate Pre-clinical Clinical
MB5029 αPD-1/IL-2v
Bi-specific fusion protein
Solid tumors
  • POC
  • Candidate
  • Pre-clinical
  • Clinical

MB4 aPD-1/aVEGF/IL-2v
Tri-specific fusion protein
Solid tumors
  • POC
  • Candidate
  • Pre-clinical
  • Clinical

MB7 aPD-1/aVEGF/IL-21v
Tri-specific fusion protein
Solid tumors
  • POC
  • Candidate
  • Pre-clinical
  • Clinical

MB9 aPD-1/aTIGIT/IL-2v
Tri-specific fusion protein
Solid tumors
  • POC
  • Candidate
  • Pre-clinical
  • Clinical